ZGN-1061 (Aclimostat) is a MetAP2 enzyme inhibitor with demonstrated efficacy and safety in preclinical studies; it shows effects similar to beloranib in reducing body weight, improving metabolic parameters in mouse models of obesity and insulin resistance, and modulating gene transcription in HepG2 cells.